Download PDF
Phlebologie 2011; 40(04): 187-194
DOI: 10.1055/s-0037-1621772
Originalarbeiten
Schattauer GmbH

Peak and baseline concentrations of fondaparinux during prophylactic therapy

Results of a prospective investigation under „real life” clinical practice conditionsGipfel- und Talspiegel-Konzentrationen von Fondaparinux während prophylaktischer BehandlungErgebnisse einer prospektiven Untersuchung unter klinischen „real life“-Be dingungen.
M. Schindewolf
1   Department of Internal Medicine, Division of Vascular Medicine and Haemostaseology, J.W. Goethe University Hospital Frankfurt am Main, Germany
,
R. Kanagendran
1   Department of Internal Medicine, Division of Vascular Medicine and Haemostaseology, J.W. Goethe University Hospital Frankfurt am Main, Germany
,
J. Scheuermann
1   Department of Internal Medicine, Division of Vascular Medicine and Haemostaseology, J.W. Goethe University Hospital Frankfurt am Main, Germany
,
H. Ackermann
2   Department of Biomathematics, J.W. Goethe University Hospital Frankfurt am Main, Germany
,
R. Kaufmann
3   Department of Dermatology, J.W. Goethe University Hospital Frankfurt am Main, Germany
,
W.-H. Boehncke
3   Department of Dermatology, J.W. Goethe University Hospital Frankfurt am Main, Germany
,
R. J. Ludwig
4   Department of Dermatology, University Hospital Luebeck, Germany
,
Z. Wolf   *
1   Department of Internal Medicine, Division of Vascular Medicine and Haemostaseology, J.W. Goethe University Hospital Frankfurt am Main, Germany
,
E. Lindhoff-Last   *
1   Department of Internal Medicine, Division of Vascular Medicine and Haemostaseology, J.W. Goethe University Hospital Frankfurt am Main, Germany
› Author Affiliations Financial disclosures: MS has received a speaking fee from GlaxoSmithKline (March 18, 2008 and February 17, 2011). ELL has received consulting fees from Bayer, Bioscientia, Boehringer-Ingelheim, GlaxoSmithKline, and Sanofi-Aventis. RJL has received consulting fees and grants from Biogen-Idec, Biotest AG, Abbott-Germany, and grants from Dompe pharma and Eroimmun AG.
Further Information

Publication History

Received:30 May 2011

Accepted:21 June 2011

Publication Date:
30 December 2017 (online)

    Permissions and Reprints

Summary

Fondaparinux is widely approved for prophylaxis and treatment of venous thromboembolic events (VTE). However, its longer half-life time compared to heparins limits its peri-procedural use.

Aim: To investigate 3h peak and 24h baseline concentrations of fondaparinux when administered for prophylaxis (1 x 2.5 mg qd). Secondary outcome measures: incidences of VTE, bleedings, HIT, allergic skin reactions, 30 days mortality.

Patients, methods: Between 02/2010 and 03/2011, 3h peak and 24h baseline levels of fondaparinux were measured with a chromogenic anti-FXa method in 75 consecutive patients. Medical data were obtained from patients' records.

Results: The 5% and 95% percentile of the 3h peak level were 0.20 μg/ml and 0.83 μg/ml (median: 0.53 μg/ml), and of the 24h baseline level 0.08 μg/ml and 0.53 μg/ml (median 0.21 μg/ml), respectively. An inverse correlation was found between fondaparinux levels and GFRs (rho=-0.617 (3h); rho=-0.648 (24h); p=0.01). Shorter (≤5 days) or longer (≥8 days) duration of prior fondaparinux exposure showed no significantly different 3h peak/24h baseline levels (p>0.6). One progressive thrombosis occurred but no major bleedings, HIT, allergic skin reactions or fatalities.

Conclusions: After fondaparinux exposure, >75% of the patients still had relevant prophylactic 24h baseline levels. This did not coincide with a high rate of bleeding events. Due to the low patient number in this study undergoing surgery or interventions, it remains to be investigated whether or at which concentrations the bleeding risk is increased when baseline levels are within prophylactic ranges.

Zusammenfassung

Hintergrund: Das synthetische Pentasaccharid Fondaparinux, ein indirekter Faktor Xa-Inhibitor, besitzt eine breite Zulassung in der Prophylaxe und Therapie von thromboembolischen Komplikationen. Es hat ein deutlich niedrigeres Risiko für HIT und allergische Reaktionen im Vergleich zu Heparinen. Allerdings bestehen aufgrund seiner längeren Halbwertszeit Einschränkungen im peri-operativen und -inter-ventionellen Bereich, während es für Heparine klare Bridging-Empfehlungen gibt.

Ziel der Untersuchung war es, die 3h-Gipfelund 24h-Talspiegel unter prophylaktischer Fondaparinuxgabe (1 x 2,5 mg/die) und die Häufigkeiten hierunter auftretender Komplikationen (venöse thromboembolische Komplikationen, Blutungen, HIT, allergische Hautreaktionen, 30-Tages-Mortalität) zu ermitteln.

Patienten, Methoden: Zwischen Februar 2010 und März 2011 wurden bei 75 konsekutiven internistischen und chirurgischen Patienten Fondaparinux 3h-Gipfel- und 24h-Talspiegel mittels einer chromogenen anti-FXa-Methode gemessen. Die Erhebung der medizinischen Daten sowie der Komplikationen erfolgte aus den Krankenakten.

Ergebnisse: Die 5% und 95% Perzentilen der 3h Gipfelspiegel lagen bei 0,20 μg/ml bzw. 0,83 μg/ml (Median: 0,53 μg/ml), und der 24h Talspiegel bei 0,08 μg/ml bzw. 0,53 μg/ml (Median: 0,21 μg/ml). Sie waren signifikant, invers negativ mit der glomerulären Filtrationsrate (GFR) korreliert (Spearman Korrelationskoeffizient: rho=-0.617 (3h); rho=-0.648 (24h), p= 0.01) Es ergaben sich keine signifikanten Unterschiede hinsichtlich der gemessenen Fondaparinuxkonzentrationen bei kürzerer (≤ 5 Tage) oder längerer (≥ 8 Tage) vorangehender Fondaparinuxgabe. Die Rate an Komplikationen war niedrig: es traten eine progrediente venöse Thrombose, jedoch keine „Major“-Blutungskomplikationen, HIT, allergische Hautreaktionen oder Todesfälle auf.

Schlussfolgerung: Überraschenderweise wie-sen >75% der Patienten nach 24 Stunden Talspiegel auf, die noch im prophylaktischen Zielbereich lagen. Eine vermehrte Inzidenz von Blutungskomplikationen war nicht zu verzeichnen. Um eine Aussage treffen zu können, ob und ab welchen gemessenen Anti-Xa-Spiegeln mit einem gehäuften Auftreten von Blutungen zu rechnen ist, und wann eine prophylaktische Therapie mit Fondaparinux präoperativ/-interventionell abgesetzt warden sollte, sind größere Fallzahlen solcher Patienten notwendig, die sich einer Operation oder einer Intervention unterziehen.

Keywords

Fondaparinux - pharmacokinetics - peak level - baseline level

Schlüsselwörter

Fondaparinux - Pharmakokinetik - Gipfelspiegel - Talspiegel

* equal contributors


 

  • References

  • 1 Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991; 350: 30-33.
    Google Scholar
  • 2 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S.
    CrossrefGoogle Scholar
  • 3 Harrington RA, Becker RC, Cannon CP. et al. Anti thrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 670S-707S.
    CrossrefPubMedGoogle Scholar
  • 4 Bauersachs RM. The CALISTO study [German]. Phlebologie 2011; 40: 79-83.
    Article in Thieme ConnectGoogle Scholar
  • 5 Schindewolf M, Scheuermann J, Beyer-Westendorf J. et al. German Registry for use of fondaparinux in HIT or suspected HIT – preliminary data. Haemostaseologie 2011; 31: A10
    Google Scholar
  • 6 Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
    CrossrefGoogle Scholar
  • 7 Schindewolf M, Scheuermann J, Kroll H. et al. Low allergenic potential with fondaparinux: Results of a prospective investigation. Mayo Clin Proc 2010; 85: 913-919.
    CrossrefGoogle Scholar
  • 8 Schiffner R, Glassl A, Landthaler M, Stolz W. Tolerance of desirudin in a patient with generalized eczema after intravenous challenge with heparin and a delayed-type skin reaction to high and low molecular weight heparins and heparinoids. Contact Dermatitis 2000; 42: 49
    Google Scholar
  • 9 Schindewolf M, Schwaner S, Wolter M. et al. Incidence and causes of heparin-induced skin lesions. CMAJ 2009; 181: 477-481.
    CrossrefGoogle Scholar
  • 10 Schindewolf M, Kahle B, Lindhoff-Last E, Ludwig RJ. Heparin-induced skin lesions: More common than suspected. Phlebologie 2010; 39: 5-11.
    Article in Thieme ConnectGoogle Scholar
  • 11 Schindewolf M, Ludwig RJ, Wolter M. et al. Diagnosis of heparin-induced delayed-type hypersensitivity. Phlebologie 2010; 39: 226-231.
    Article in Thieme ConnectGoogle Scholar
  • 12 Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
    CrossrefGoogle Scholar
  • 13 Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). Thromb Haemost 2007; 5: 2211-2218.
    CrossrefGoogle Scholar
  • 14 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Thromb Haemost 2005; 3: 692-694.
    CrossrefGoogle Scholar
  • 15 Schulman S, Angeras U, Bergqvist D. et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Thromb Haemost 2010; 8: 202-204.
    CrossrefGoogle Scholar
  • 16 Marshall M. Duplex sonography phlebologically accentuated. Phlebologie 2010; 39: 139-151.
    Article in Thieme ConnectGoogle Scholar
  • 17 Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T's score. Thromb Haemost 2010; 8: 1483-1485.
    CrossrefGoogle Scholar
  • 18 Bauersachs RM, Berger K, Hankowitz J. et al. Prophylaxis, diagnosis and therapy of surgery-related complications in orthopedic and trauma surgery. Eur J Trauma 2005; 31: 158-167.
    CrossrefGoogle Scholar
  • 19 Colwell Jr. CW, Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21: 36-45.
    CrossrefPubMedGoogle Scholar
  • 20 Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2655.
    CrossrefGoogle Scholar
  • 21 Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-781.
    Article in Thieme ConnectGoogle Scholar
  • 22 Elalamy I, Tribout B. Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal. Thromb Haemost 2008; 6: 1242-1243. author reply 1243–1246
    CrossrefGoogle Scholar
  • 23 Damgen-von Brevern G, Klaffling C, Lindhoff-Last E. Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level. Hamostaseologie 2005; 25: 281-285.
    Article in Thieme ConnectGoogle Scholar
  • 24 Decousus H, Prandoni P, Mismetti P. et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010; 363: 1222-1232.
    CrossrefGoogle Scholar
  • 25 Singelyn FJ, Verheyen CC, Piovella F. et al. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 2007; 105: 1540-1547.
    CrossrefGoogle Scholar
  • 26 Gogarten W, Van Aken H, Büttner J. et al. Regional anaesthesia and thromboembolism prophylaxis/ anticoagulation – Revised recommendations of the German Society of Anaesthesiology and Intensive Care Medicine [German]. Anästh Intensivmed 2007; 48: S109-S124.
    Google Scholar
  • 27 Hammerstingl C, Omran H, Tripp C, Poetzsch B. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin ? A pilot study. Thromb Haemost 2009; 101: 325-332.
    Article in Thieme ConnectGoogle Scholar
  • 28 Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009; 20: 114-121.
    CrossrefGoogle Scholar
  • 29 Donat F, Duret JP, Santoni A. et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl (Suppl. 02) 1-9.
    Google Scholar
  • 30 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
    CrossrefGoogle Scholar
  • 31 Lassen MR, Ageno W, Borris LC. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
    CrossrefGoogle Scholar
  • 32 Cohen AT, Spiro TE, Buller HR. et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011; 31: 407-416.
    CrossrefGoogle Scholar
  • 33 Cohen AT, Davidson BL, Gallus AS. et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-329.
    CrossrefGoogle Scholar
  • 34 Handschin AE, Trentz OA, Hoerstrup SP. et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-183.
    CrossrefGoogle Scholar
  • 35 Turpie A, Bauer K, Eriksson B, Lassen M. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90: 364-366.
    Article in Thieme ConnectGoogle Scholar